The Technology
Precision Cancer Treatment with
Dye Drug Conjugates.
​Lahavida has made significant strides in cancer research with its proprietary Dye Drug Conjugate Technology. Our preclinical data demonstrate that these new Dye Drug Conjugates precisely target lung, breast, and colon cancer cells by combining tumor-targeting dyes, specialized linkers, and standard-of-care chemotherapy drugs. The drug activates within cancer cells, destroying them while sparing healthy tissues. Preliminary studies in 2D cell cultures and mice show that Dye Drug Conjugates effectively target tumors, deliver chemotherapy, and demonstrate strong cancer-killing efficacy.​​
Dye Drug Conjugates (DDCs)
Advantages:
-
Potential to treat over 30 different cancer types.
-
Accurate targeting of cancerous cells.
-
Low systemic toxicity.
-
High payload delivery.
-
Small molecule.
-
Streamlined and consistent manufacturing.
-
Cost-effective and accessible.
